BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.108 | 35.761589404 | 0.302 | 0.42 | 0.3001 | 924139 | 0.35783491 | CS |
4 | -0.05 | -10.8695652174 | 0.46 | 0.5566 | 0.3001 | 992011 | 0.40433296 | CS |
12 | -0.14 | -25.4545454545 | 0.55 | 0.83 | 0.3001 | 656197 | 0.49545728 | CS |
26 | -0.9 | -68.7022900763 | 1.31 | 1.37 | 0.3001 | 610533 | 0.67203364 | CS |
52 | -2.59 | -86.3333333333 | 3 | 4.17 | 0.3001 | 827349 | 1.91035284 | CS |
156 | -22.31 | -98.1954225352 | 22.72 | 34.125 | 0.3001 | 1025021 | 7.6385415 | CS |
260 | -9.58 | -95.8958958959 | 9.99 | 74.89 | 0.3001 | 805044 | 15.08776864 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales